129 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
of successful safety and dose-finding clinical studies. RCT-01 and RCS-01 are exclusively licensed in Greater China to YOFOTO (China) Health Company
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
or corticosteroids, which are limited in efficacy;
belief that the data from a phase 1/2 clinical trial to test the safety and efficacy of injections … to a phase 2 trial and the design of such a dose-finding trial;
belief that the data from the phase 1 clinical trial to test the safety and certain
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
, which are limited in efficacy;
belief that the data from a phase 1/2 clinical trial to test the safety and efficacy of injections of RCT-01 on patients … and the design of such a dose-finding trial;
belief that the data from the phase 1 clinical trial to test the safety and certain biological outcomes
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
19 Oct 23
Current report (foreign)
1:45pm
has been the subject of successful safety and dose-finding clinical studies and is now the subject of its third clinical study evaluating efficacy
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
4 Oct 23
RepliCel Provides Default Status Update and Announces Shareholder Approval of Equity Incentive Plan
2:23pm
for hair restoration. RCH-01 has been the subject of successful safety and dose-finding clinical studies and is now the subject of its third clinical
6-K
EX-99.2
5gi0xmz l8
13 Sep 23
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
EX-99.1
puzjtef68hgdpsolil
13 Sep 23
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
EX-99.1
16gdw3y4dnx4ld6vz
7 Sep 23
Current report (foreign)
12:26pm
6-K
EX-99.1
j2piytdisbgamho07
29 Aug 23
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is appointed Chief Financial Officer
1:14pm
6-K
EX-99.2
kwdx19ds5qlv 0ixh8u
17 Aug 23
Annual General and Special Meeting
11:22am
6-K
EX-99.4
bgm47s8ae5kg07o
17 Aug 23
Annual General and Special Meeting
11:22am
6-K
EX-99.2
g3ug5w ew8rb6e6y
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.1
p2njsv5y81ols 9y
18 May 23
RepliCel Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options
1:58pm
6-K
EX-99.5
i8sxbbadj7u505wkwx2k
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.2
xqbn 4pyms5
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.1
fnq 271ugtydnd8
25 Oct 22
Current report (foreign)
12:27pm
6-K
EX-99.2
gbsdet8g70irfh r6hi
25 Oct 22
Current report (foreign)
12:27pm
20-F/A
t51xscfbs8az
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.1
xxe62n4ssl624zschs1n
6 Sep 22
RepliCel Announces Non-brokered Private Placement
2:35pm